Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NNMT | P40261 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.34 |
| ▸ | NQO2 | P16083 | 3/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | CLK3 | P49761 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2081951 | 0.87 | POLB (0.35) | POLBTDP1NNMTMTNR1AMTNR1B | |
| SCHEMBL9202948 | 0.84 | POLB (0.38) | POLBTDP1NNMTMTNR1AMTNR1B | |
| SCHEMBL17978162 | 0.82 | POLB (0.33) | POLBTDP1NNMTMTNR1AMTNR1B | |
| SCHEMBL10264276 | 0.81 | PDE10A (0.39) | MTNR1AMTNR1BTXNRD1 | |
| SCHEMBL2078322 | 0.80 | MTNR1A (0.40) | POLBTDP1NNMTMTNR1AMTNR1B | |
| SCHEMBL2082030 | 0.80 | NNMT (0.36) | POLBTDP1NNMTMTNR1AMTNR1B | |
| SCHEMBL30908739 | 0.80 | SMN1; SMN2 (0.39) | POLBTDP1NNMTKDM4EALDH1A1 | |
| SCHEMBL19838014 | 0.79 | SIRT2 (0.34) | POLBTDP1NNMTNQO2SIRT2 | |
| SCHEMBL19810782 | 0.79 | PGK1 (0.37) | POLBTDP1NNMTMTNR1AMTNR1B | |
| SCHEMBL28594753 | 0.79 | KDM4E (0.39) | POLBTDP1NNMTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503471-B2 | Triazatricycle compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250282782-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORP (US) | 2025-09-11 | — | — | US | disclosed |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2025096751-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ESPERION THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4506035-A2 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119212994-A | Pyrazolopyrazine compounds as SHP2 inhibitors | 建新公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4448526-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2024-10-23 | — | — | EP | disclosed |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-3768668-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240124442-A1 | TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS | AMGEN INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-20090062306-A1 | NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME | KOWA COMPANY, LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090054474-A1 | Novel pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same | KOWA COMPANY, LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1899334-B1 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| EP-1899334-B1 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| US-7417054-B2 | Naphthyridine compounds | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-08-26 | — | — | US | disclosed |
| US-7417054-B2 | Naphthyridine compounds | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-08-26 | — | — | US | disclosed |
| US-7417054-B2 | Naphthyridine compounds | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-08-26 | — | — | US | disclosed |
| EP-1899334-A2 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006138714-A2 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287292-A1 | NAPHTHYRIDINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287292-A1 | NAPHTHYRIDINE COMPOUNDS | HRH3, HRH4, HRH1 | POLB 3248/4885TDP1 3315/4885NNMT 137/4885 |
| US-20250282782-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | PTPN5, PTPN2, PTPRJ | POLB 4537/4885TDP1 2457/4885NNMT 2593/4885 |
| US-20090054474-A1 | Novel pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same | CETP, TYMP, MTTP | POLB 369/4885TDP1 126/4885NNMT 165/4885 |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | POLB 3791/4885TDP1 2083/4885NNMT 2441/4885 |
| US-20090062306-A1 | NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME | CETP, MTTP, NPC1L1 | POLB 2135/4885TDP1 855/4885NNMT 599/4885 |
| US-20240124442-A1 | TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | POLB 1837/4885TDP1 923/4885NNMT 193/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | POLB 3791/4885TDP1 2083/4885NNMT 2441/4885 |
| US-12503471-B2 | Triazatricycle compounds for the treatment of autoimmune disease | SSB, HLA-DRB1, PKD1 | POLB 2057/4885TDP1 2522/4885NNMT 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.